Solventum is leveraging a $93B TAM with strong global presence, trusted brands, and innovation across wound care, dental, and health IT. Margin expansion and restructuring savings, it for sustained growth and shareholder value.

Strength across all the segments, a focus on innovation and accretive buyouts are aiding ITT. Its efforts to reward shareholders add to its appeal.

Given its innovation prowess and product depth, Viavi is well-positioned to leverage major secular growth trends in 5G, fiber and 3D sensing. Its cash position is also stable.

Illumina’s breakthrough innovations and productivity enhancements are poised to help it achieve its refreshed strategic goals. Robust prospects in the NGS market are

Kohl’s gains traction through Sephora expansion, tighter expense management, improved digital capabilities and momentum in home décor, gifting, impulse and other growth categories.

Cambium is well-poised to benefit from robust demand for wireless broadband connectivity, proprietary software and new product launches. Cloud-based network management software and focus on cost optimization are tailwinds.

The company’s strategic investment plans and consistent customer additions to its natural gas segment will further boost its financials. Also, its regular dividends acts as a tailwind.

Strength in most of the segments, solid order rate and the Evoqua buyout are expected to fortify Xylem’s growth. The shareholder-friendly policies spark optimism.

Fortive's growth in Intelligent Operating Solutions and Advanced Healthcare segments, along with margin expansion initiatives, bodes well.

Solid contributions from residential customers, returns within one year of investment, customer additions and positive regulatory outcomes will continue to boost the company’s performance.